Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Medioni

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Plos One|September 14, 2023
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)Karen Leroy, Clarisse Audigier Valette, Jérôme Alexandre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid TumorsLuis Teixeira, Jacques Medioni, Julie Garibal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2009
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patientsAntonin Schmitt, Laurence Gladieff, Amélie Lansiaux, et al.
JAMA Network Open|April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic AberrationsPhilip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
British Journal of Cancer|January 25, 2024
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine careBenoit Blanchet, Alexandre Xu-Vuilard, Anne Jouinot, et al.
Gynecologic Oncology|February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO studyFlorence Joly, Michel Fabbro, Philippe Follana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2025
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA TrialAntonio Llombart-Cussac, Catherine Harper-Wynne, Antonia Perelló, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2019
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumoursRobin L Jones, Mark J Ratain, Peter J O'Dwyer, et al.
Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.
The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid CancersLori J Wirth, Eric Sherman, Bruce Robinson, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Plos One|September 14, 2023
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)Karen Leroy, Clarisse Audigier Valette, Jérôme Alexandre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid TumorsLuis Teixeira, Jacques Medioni, Julie Garibal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2009
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patientsAntonin Schmitt, Laurence Gladieff, Amélie Lansiaux, et al.
JAMA Network Open|April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic AberrationsPhilip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
British Journal of Cancer|January 25, 2024
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine careBenoit Blanchet, Alexandre Xu-Vuilard, Anne Jouinot, et al.
Gynecologic Oncology|February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO studyFlorence Joly, Michel Fabbro, Philippe Follana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2025
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA TrialAntonio Llombart-Cussac, Catherine Harper-Wynne, Antonia Perelló, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2019
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumoursRobin L Jones, Mark J Ratain, Peter J O'Dwyer, et al.
Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.
The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid CancersLori J Wirth, Eric Sherman, Bruce Robinson, et al.
Pageof 6